Point Blank Medical Pty Ltd are official agents of Hemoblast Bellows, a hemostatic agent developed by Dilon Technologies, aimed at enhancing surgical outcomes by providing rapid and effective bleeding control. The Hemoblast Bellows device, a cutting-edge solution in hemostasis, is designed to address bleeding during surgeries with its unique powdered hemostat delivery system. This partnership marks a significant step for Point Blank Medical in broadening its portfolio of advanced surgical products, ensuring that healthcare professionals have access to the latest tools to improve patient care.
Dilon Technologies’ Hemoblast Bellows has gained attention for its ease of use and effectiveness in a variety of surgical procedures. The device’s ability to deliver a precise amount of hemostatic powder directly to the bleeding site minimizes waste and optimizes results, making it a valuable asset in the operating room. By distributing this innovative product, Point Blank Medical is set to play a crucial role in improving surgical outcomes, ultimately benefiting patients across a range of medical specialties.
For further information, please contact sales@pointblankmedical.com.
